Licensing Clinical-Stage Assets to Greater China

11:00 AM - 12:15 PM, Tuesday, June 9, 2020 ・ Room 6F
The rise of Chinese bio and pharma companies has provided many US and European companies with the opportunity to raise non-dilutive capital by licensing rights to clinical stage assets in the Greater China Territory. What strategies and tactics should be considered, what peculiarities exist within this Territory, what is the process like and what key deal terms will be negotiated?
Chief Business Officer
Everest Medicines
Executive Director of Strategic Alliances
Spero Therapeutics